{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"19.7","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"To evaluate the confirmed response rate of pazopanib in patients with MPM based on the RECIST criteria for MPM. Responses are confirmed by repeat assessments that are be performed no less than 4 weeks after the criteria for response are first met.\n\nComplete Response (CR): Disappearance of all target lesions.\n\nPartial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","populationDescription":"All 34 participants were evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"Participants will be evaluated every cycle during treatment, up to 2 years","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of patients"}